The Macrophage Activator GcMAF-RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2–M1 Macrophage Reprogramming

Figure 4

The phenotype and synthesis of specific anti-inflammatory factor mRNAs in the peritoneal macrophage population from intact mice, tumor-bearing mice, and tumor-bearing mice after treatment with Karanahan technology and in synergy with GcMAF-RF. (a) Characterization of the peritoneal macrophage phenotype isolated from intact mice, tumor-bearing mice, and mice treated with Karanahan technology and in synergy with GcMAF-RF. The results of flow cytometry analysis for myeloid-derived suppressor cell markers of monocytes (CD11b+Ly-6C+) of peritoneal macrophage populations isolated from intact mice and mice treated with Karanahan technology and in synergy with GcMAF-RF relative to tumor-bearing mice (indicated by a red line). Floating bars (min to max); line at median. The black asterisk denotes the significant difference with control (tumor-bearing mice); $—indicates the significant difference with intact mice, ; Mann–Whitney U test. (b) Relative levels of mRNA expression of some anti-inflammatory factor genes in peritoneal macrophage populations isolated from intact mice and mice treated with Karanahan technology and in synergy with GcMAF-RF in comparison with peritoneal macrophages isolated from tumor-bearing mice (their expression level = 1; the Y-axis is logarithmic). Box and whisker plot.

(a)

(b)